<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en-US" data-colors-preset="contrast" data-primary-color="#307FFF"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta charset="UTF-8"><meta name="robots" content="noindex">  <meta name="built-on" content="2024-01-01T12:25:15.7990371"><meta name="build-number" content="${buildNumber}">       <title>华东医药：目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊 | 20231016</title><script id="virtual-toc-data" type="application/json">[]</script><script id="topic-shortcuts" type="application/json"></script><link href="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.css" rel="stylesheet">   <link rel="apple-touch-icon" sizes="180x180" href="https://jetbrains.com/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="https://jetbrains.com/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="https://jetbrains.com/favicon-16x16.png"><link rel="manifest" href="https://jetbrains.com/site.webmanifest"><link rel="mask-icon" href="https://jetbrains.com/safari-pinned-tab.svg" color="#000000"><meta name="msapplication-TileColor" content="#000000"/><meta name="msapplication-TileImage" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-144x144.png"/><meta name="msapplication-square70x70logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-70x70.png"/><meta name="msapplication-square150x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-150x150.png"/><meta name="msapplication-wide310x150logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x150.png"/><meta name="msapplication-square310x310logo" content="https://resources.jetbrains.com/storage/ui/favicons/mstile-310x310.png"/>  <meta name="image" content=""><!-- Open Graph --><meta property="og:title" content="华东医药：目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊 | 20231016"/><meta property="og:description" content=""/><meta property="og:image" content=""/><meta property="og:site_name" content="20231016 Help"/><meta property="og:type" content="website"/><meta property="og:locale" content="en_US"/><meta property="og:url" content="3268.html"/><!-- End Open Graph --><!-- Twitter Card --><meta name="twitter:card" content="summary_large_image"><meta name="twitter:site" content=""><meta name="twitter:title" content="华东医药：目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊 | 20231016"><meta name="twitter:description" content=""><meta name="twitter:creator" content=""><meta name="twitter:image:src" content=""><!-- End Twitter Card --><!-- Schema.org WebPage --><script type="application/ld+json"> { "@context": "http://schema.org", "@type": "WebPage", "@id": "3268.html#webpage", "url": "3268.html", "name": "华东医药：目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊 | 20231016", "description": "", "image": "", "inLanguage":"en-US" }</script><!-- End Schema.org --><!-- Schema.org WebSite --><script type="application/ld+json"> { "@type": "WebSite", "@id": "/#website", "url": "/", "name": "20231016 Help" }</script><!-- End Schema.org --></head>      <body data-id="3268" data-main-title="华东医药：目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊" data-article-props="{&quot;seeAlsoStyle&quot;:&quot;links&quot;}"  data-template="article"  data-breadcrumbs=""  >   <div class="wrapper"><main class="panel _main"><header class="panel__header"><div class="container"><h3>20231016  Help</h3><div class="panel-trigger"></div></div></header><section class="panel__content"><div class="container"><article class="article" data-shortcut-switcher="inactive"><h1 data-toc="3268"   id="3268.md">华东医药：目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊</h1>  <p id="d22787b_15"><span class="control" id="d22787b_16">界面快报</span></p><p id="d22787b_17"><span class="control" id="d22787b_18">2023-10-16 15:04</span></p><p id="d22787b_19"><span class="control" id="d22787b_20">https://www.jiemian.com/article/10236096.html</span></p><p id="d22787b_21">华东医药10月16日在互动平台上称，在肥胖或体重超重患者的治疗领域，公司目前已上市的医药产品有利拉鲁肽注射液和奥利司他胶囊。作为中国大陆首家也是目前唯一一家拥有利拉鲁肽注射液肥胖或超重适应症上市批文的企业，公司十分重视该产品的上市推广，目前正积极开展院内和院外渠道的市场覆盖和销售工作。此外，公司在减肥领域围绕GLP-1靶点进行了差异化布局，已构筑包括口服、注射剂在内的长效及多靶点全球创新药和生物类似药相结合的全方位产品管线，除了已上市的利拉鲁肽注射液，目前在研的还包括生物类似药司美格鲁肽注射液、全球创新口服小分子GLP-1受体激动剂HDM1002、双靶点激动剂HDM1005及SCO-094、长效三靶点激动剂DR10624等多款产品。</p><div class="last-modified"> Last modified: 01 一月 2024</div><div data-feedback-placeholder="true"></div><div class="navigation-links _bottom">  <a class="navigation-links__prev" href="3269.html">华东医药：公司司美格鲁肽注射液糖尿病适应症目前处于临床Ⅲ期入组阶段</a>   <a class="navigation-links__next" href="3267.html">奥比中光：已与深圳市教育信息技术中心、上海宝山区教育局等单位建立友好合作并落地部分项目</a>  </div></article><div id="disqus_thread"></div></div></section></main></div>  <script src="https://resources.jetbrains.com/writerside/apidoc/6.6.6-b205/app.js"></script></body></html>